hahah no. stock is not going anywhere. the drug actually works and helps patients for the approved indication. technically this should have no price impact since FDA is not suspending sales of it. FDA is basically telling them to shut their mouths on national tv.
"Aegerion receives FDA warning letter on marketing of Juxtapid
The FDA sent a Warning Letter to Aegerion notifying the company that the Office of Prescription Drug Promotion of the U.S. FDA has become aware of statements that the company's CEO Marc Beer made regarding Juxtapid during broadcast interviews on CNBC’s television show, “Fast Money,” that aired on June 5, and October 31. The statements provide evidence that Juxtapid is intended for new uses, for which it lacks approval and for which its labeling does not provide adequatedirections for use, which renders Juxtapid misbranded within the meaning of the Federal Food Drug and Cosmetic Act and makes its distribution violative of the FD&C Act." Reference Link